Charles River Laboratories International, Inc. $CRL Shares Sold by Amundi

Key Points

• Amundi significantly reduced its stake in Charles River Laboratories by 76.7%, leaving it with 16,347 shares valued at approximately $2.3 million after selling 53,919 shares in the first quarter.
• Charles River Laboratories has seen mixed changes in institutional investor positions, with Brooklyn Investment Group increasing its stake by 93.5% while others, like Amundi, have reduced theirs.
• Recent analyst ratings have varied, with six analysts assigning a "Buy" rating and a consensus target price of $177.07, indicating a cautious outlook on the company’s stock performance.

Amundi lessened its position in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 76.7% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 16,347 shares of the medical research company's stock after selling 53,919 shares during the quarter. Amundi's holdings in Charles River Laboratories International were worth $2,305,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Royal Bank of Canada lifted its holdings in Charles River Laboratories International by 304.7% in the 1st quarter. Royal Bank of Canada now owns 627,710 shares of the medical research company's stock valued at $94,484,000 after purchasing an additional 472,606 shares in the last quarter. Canada Pension Plan Investment Board lifted its stake in Charles River Laboratories International by 3,090.9% in the 1st quarter. Canada Pension Plan Investment Board now owns 105,300 shares of the medical research company's stock worth $15,850,000 after purchasing an additional 102,000 shares in the last quarter. State of Wyoming lifted its stake in Charles River Laboratories International by 16.5% in the 1st quarter. State of Wyoming now owns 1,468 shares of the medical research company's stock worth $221,000 after purchasing an additional 208 shares in the last quarter. Landscape Capital Management L.L.C. purchased a new position in Charles River Laboratories International in the 1st quarter worth approximately $503,000. Finally, Broyhill Asset Management LLC lifted its stake in Charles River Laboratories International by 2.5% in the 1st quarter. Broyhill Asset Management LLC now owns 13,259 shares of the medical research company's stock worth $1,996,000 after purchasing an additional 325 shares in the last quarter. Hedge funds and other institutional investors own 98.91% of the company's stock.

Insider Activity at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction on Monday, August 18th. The shares were sold at an average price of $157.60, for a total value of $126,080.00. Following the completion of the transaction, the executive vice president owned 24,116 shares in the company, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 1.30% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CRL has been the topic of a number of analyst reports. Wall Street Zen upgraded Charles River Laboratories International from a "buy" rating to a "strong-buy" rating in a research report on Saturday. Redburn Atlantic upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and reduced their price target for the stock from $188.00 to $182.00 in a report on Friday, May 23rd. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Evercore ISI lifted their price target on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. Finally, JPMorgan Chase & Co. lifted their target price on shares of Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a research note on Thursday, August 7th. Six investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus price target of $177.07.

Charles River Laboratories International Trading Up 0.6%

NYSE CRL traded up $0.88 during trading on Wednesday, hitting $152.48. The stock had a trading volume of 1,379,194 shares, compared to its average volume of 719,351. The company has a market capitalization of $7.50 billion, a PE ratio of -114.65, a PEG ratio of 4.85 and a beta of 1.47. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average price of $160.49 and a 200 day moving average price of $148.56. Charles River Laboratories International, Inc. has a twelve month low of $91.86 and a twelve month high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.62. The company had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.Charles River Laboratories International's revenue was up .6% compared to the same quarter last year. During the same period in the previous year, the company posted $2.80 EPS. As a group, equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).